KRAS and non-small cell lung carcinoma: TMB testing of clinical samples from 4017 driver gene-positive NSCLC patients showed higher TMB levels in KRAS mutant patients compared to other driver gene-positive patients (median 7.8 mut/Mb, n = 2240), suggesting higher immunogenicity of KRAS mutant tumors 20.